Long-term efficacy and safety of adalimumab in 4-12 year old patients with juvenile idiopathic arthritis

Detalles Bibliográficos
Autores principales: Ruperto, N, Lovell, DJ, Reiff, A, Gamir, M, Higgins, G, Koné-Paut, I, Jones, OY, Chalom, E, Ilowite, N, Wouters, C, McIlraith, MJ, Liu, S, Kupper, H, Giannini, EH, Martini, A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Oral Presentation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3194421/
http://dx.doi.org/10.1186/1546-0096-9-S1-O26
_version_ 1782213968528408576
author Ruperto, N
Lovell, DJ
Reiff, A
Gamir, M
Higgins, G
Koné-Paut, I
Jones, OY
Chalom, E
Ilowite, N
Wouters, C
McIlraith, MJ
Liu, S
Kupper, H
Giannini, EH
Martini, A
author_facet Ruperto, N
Lovell, DJ
Reiff, A
Gamir, M
Higgins, G
Koné-Paut, I
Jones, OY
Chalom, E
Ilowite, N
Wouters, C
McIlraith, MJ
Liu, S
Kupper, H
Giannini, EH
Martini, A
author_sort Ruperto, N
collection PubMed
description
format Online
Article
Text
id pubmed-3194421
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-31944212011-10-18 Long-term efficacy and safety of adalimumab in 4-12 year old patients with juvenile idiopathic arthritis Ruperto, N Lovell, DJ Reiff, A Gamir, M Higgins, G Koné-Paut, I Jones, OY Chalom, E Ilowite, N Wouters, C McIlraith, MJ Liu, S Kupper, H Giannini, EH Martini, A Pediatr Rheumatol Online J Oral Presentation BioMed Central 2011-09-14 /pmc/articles/PMC3194421/ http://dx.doi.org/10.1186/1546-0096-9-S1-O26 Text en Copyright ©2011 Ruperto et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Oral Presentation
Ruperto, N
Lovell, DJ
Reiff, A
Gamir, M
Higgins, G
Koné-Paut, I
Jones, OY
Chalom, E
Ilowite, N
Wouters, C
McIlraith, MJ
Liu, S
Kupper, H
Giannini, EH
Martini, A
Long-term efficacy and safety of adalimumab in 4-12 year old patients with juvenile idiopathic arthritis
title Long-term efficacy and safety of adalimumab in 4-12 year old patients with juvenile idiopathic arthritis
title_full Long-term efficacy and safety of adalimumab in 4-12 year old patients with juvenile idiopathic arthritis
title_fullStr Long-term efficacy and safety of adalimumab in 4-12 year old patients with juvenile idiopathic arthritis
title_full_unstemmed Long-term efficacy and safety of adalimumab in 4-12 year old patients with juvenile idiopathic arthritis
title_short Long-term efficacy and safety of adalimumab in 4-12 year old patients with juvenile idiopathic arthritis
title_sort long-term efficacy and safety of adalimumab in 4-12 year old patients with juvenile idiopathic arthritis
topic Oral Presentation
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3194421/
http://dx.doi.org/10.1186/1546-0096-9-S1-O26
work_keys_str_mv AT ruperton longtermefficacyandsafetyofadalimumabin412yearoldpatientswithjuvenileidiopathicarthritis
AT lovelldj longtermefficacyandsafetyofadalimumabin412yearoldpatientswithjuvenileidiopathicarthritis
AT reiffa longtermefficacyandsafetyofadalimumabin412yearoldpatientswithjuvenileidiopathicarthritis
AT gamirm longtermefficacyandsafetyofadalimumabin412yearoldpatientswithjuvenileidiopathicarthritis
AT higginsg longtermefficacyandsafetyofadalimumabin412yearoldpatientswithjuvenileidiopathicarthritis
AT konepauti longtermefficacyandsafetyofadalimumabin412yearoldpatientswithjuvenileidiopathicarthritis
AT jonesoy longtermefficacyandsafetyofadalimumabin412yearoldpatientswithjuvenileidiopathicarthritis
AT chalome longtermefficacyandsafetyofadalimumabin412yearoldpatientswithjuvenileidiopathicarthritis
AT ilowiten longtermefficacyandsafetyofadalimumabin412yearoldpatientswithjuvenileidiopathicarthritis
AT woutersc longtermefficacyandsafetyofadalimumabin412yearoldpatientswithjuvenileidiopathicarthritis
AT mcilraithmj longtermefficacyandsafetyofadalimumabin412yearoldpatientswithjuvenileidiopathicarthritis
AT lius longtermefficacyandsafetyofadalimumabin412yearoldpatientswithjuvenileidiopathicarthritis
AT kupperh longtermefficacyandsafetyofadalimumabin412yearoldpatientswithjuvenileidiopathicarthritis
AT gianninieh longtermefficacyandsafetyofadalimumabin412yearoldpatientswithjuvenileidiopathicarthritis
AT martinia longtermefficacyandsafetyofadalimumabin412yearoldpatientswithjuvenileidiopathicarthritis

Ejemplares similares